ArticleScientific reports2017

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.

Riccardo Giampieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.